Literature DB >> 2039949

Valproate suppresses N-methyl-D-aspartate-evoked, transient depolarizations in the rat neocortex in vitro.

M L Zeise1, S Kasparow, W Zieglgänsberger.   

Abstract

Effects of the antiepileptic drug sodium valproate (VPA) were studied on neocortical pyramidal cells (layer II/III) of the rat in vitro by intracellular recording. VPA (0.1-1 mM) in a dose-related manner suppressed the characteristic transient depolarizations induced by N-methyl-D-aspartate (NMDA) applied iontophoretically Higher concentrations of VPA (5-10 mM) also reduced L-glutamate responses. At these concentrations VPA increased the duration of orthodromically evoked inhibitory postsynaptic potentials and reduced repetitive spike firing induced by depolarizing currents. All effects were fully reversible within about 30 min. These results suggest that an essential mode of action for the anticonvulsant VPA is the attenuation of NMDA receptor-mediated excitation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2039949     DOI: 10.1016/0006-8993(91)90078-a

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  23 in total

1.  Case files of the Children's Hospital of Michigan Regional Poison Control Center: the use of carnitine for the management of acute valproic acid toxicity.

Authors:  Abhishek Katiyar; Cynthia Aaron
Journal:  J Med Toxicol       Date:  2007-09

2.  Interactions of excitatory amino acid antagonists with conventional antiepileptic drugs.

Authors:  S J Czuczwar; W A Turski; Z Kleinrok
Journal:  Metab Brain Dis       Date:  1996-06       Impact factor: 3.584

3.  Effect of valproic acid through regulation of NMDA receptor-ERK signaling in sleep deprivation rats.

Authors:  Hae Jeong Park; Won Sub Kang; Jong Woo Paik; Jong Woo Kim
Journal:  J Mol Neurosci       Date:  2011-11-19       Impact factor: 3.444

4.  Chronological changes of MRI findings on striatal damage after acute cyanide intoxication: pathogenesis of the damage and its selectivity, and prevention for neurological sequelae: a case report.

Authors:  K Kasamo; Y Okuhata; R Satoh; M Ikeda; S Takahashi; R Kamata; Y Nogami; T Kojima
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1993       Impact factor: 5.270

Review 5.  Low threshold T-type calcium channels as targets for novel epilepsy treatments.

Authors:  Kim L Powell; Stuart M Cain; Terrance P Snutch; Terence J O'Brien
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

Review 6.  Molecular and therapeutic potential and toxicity of valproic acid.

Authors:  Sébastien Chateauvieux; Franck Morceau; Mario Dicato; Marc Diederich
Journal:  J Biomed Biotechnol       Date:  2010-07-29

Review 7.  Effects of the antiepileptic drug valproate on metabolism and function of inhibitory and excitatory amino acids in the brain.

Authors:  W Löscher
Journal:  Neurochem Res       Date:  1993-04       Impact factor: 3.996

Review 8.  Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy.

Authors:  Wolfgang Löscher
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 9.  Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders.

Authors:  Gerard Sanacora; Carlos A Zarate; John H Krystal; Husseini K Manji
Journal:  Nat Rev Drug Discov       Date:  2008-05       Impact factor: 84.694

10.  Sodium- and magnesium-valproate in vivo modulate glutamatergic and GABAergic synapses in the medial prefrontal cortex.

Authors:  Gabriella Gobbi; Luigi Janiri
Journal:  Psychopharmacology (Berl)       Date:  2006-02-22       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.